Archive for ◊ September, 2012 ◊

• Saturday, September 29th, 2012

When 59-year-old Gerald Cunha was diagnosed with a 2 1/2-foot blood clot that stretched from his knee to his abdomen, doctors prepared him for the worst. But thanks to a new clot-busting technology, Cunha survived and was able to tell his story to FoxNewsHealth.com. Cunha’s ordeal began with what he thought was just sciatica causing […]

• Tuesday, September 25th, 2012

A new virtual reality simulator – including sophisticated 3-D graphics and tactile feedback – provides neurosurgery trainees with valuable opportunities to practice essential skills and techniques for brain cancer surgery, according to a paper in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a […]

• Tuesday, September 25th, 2012

As of now, surgeons in the U.S. and Canada can take advantage of the newly launched LEGION HK Hinge Knee implant from Smith & Nephew—a product that has over 15 years of clinical history. As indicated by the company, this is the first hinged knee to be designed using normal knee kinematics, and the implant […]

• Tuesday, September 25th, 2012

Internal Fixation Systems (IFS), Inc. was founded in Miami in 2007 to market and distribute orthopedic screws, plates and implants. The company claims to offer products at half the price of their competitors. By May 2011 the company began trading as an over-the-counter stock. Investors included physicians from the Miami area. This past August a […]

• Tuesday, September 25th, 2012

9/24/2012 6:51:41 AM LIMERICK, Pa.–(BUSINESS WIRE)– Teleflex Incorporated (TFX) today announced the ARROW FlexBlock continuous peripheral nerve block catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).   The ARROW FlexBlock continuous peripheral nerve block catheter is intended for clinicians who use ultrasound-guidance when placing continuous peripheral nerve block catheters. The […]

• Tuesday, September 25th, 2012

HAZELWOOD, Mo.–(BUSINESS WIRE)– Mallinckrodt, the Pharmaceuticals business of Covidien (COV), today announced a definitive agreement to acquire CNS Therapeutics, Inc., a privately held specialty pharmaceutical company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain.   Mallinckrodt will acquire all of the […]